Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 March 2012: Short Communication  

Targeting mitochondrial biogenesis for promoting health

George B. Stefano , Celline Kim , Kirk Mantione , Federico Casares , Richard M. Kream

DOI: 10.12659/MSM.882526

Med Sci Monit 2012; 18(3): SC1-3

0 Comments

Molecular Targets for Evaluation of Mitochondrial Viability

A widely embraced set of hypotheses poses an endosymbiont model of mitochondrial development driven by evolutionary modification of permanently enslaved primordial purple non-sulphur bacteria [1]. From a teleological perspective, endosymbiotic enhancement of eukaryotic cellular energy requirements indicates a convergence of metabolic processes within the mitochondrial matrix for optimal synthesis of ATP from ADP and inorganic phosphate. Bacterial and mitochondrial ATP synthases (F-ATPases) require a defined membrane potential to achieve transductive transmembrane proton-motive force across the inner membrane linked to high efficiency of ATP production. This necessitates an evolutionarily driven retrofit of the bacterial plasma membrane into the inner mitochondrial membrane. The proton-motive force is functionally coupled via mechanical transductive events within discrete protein subunits localized to the transmembrane domains of F-ATPases and involves sequential protonation and deprotonation of glutamate side-chains of c-subunits within functional pores. Evolutionary pressure is predicted to provide an existential advantage to the host eukaryotic cell at this primal level of energy production. Recent elegant work has confirmed this key contention by demonstrating an enhanced efficiency of 2.7 vs. 3.3–5 protons per synthesized ATP molecule by eukaryotic vs. prokaryotic F-ATPases, respectively [2].

Mechanistically, endosymbiosis has apparently resulted in seamless coupling of cytochrome c oxidase (COX) to F-ATPase for maximal ATP production in respiring mitochondria, thereby effecting essential partitioning of glycolytic and TCA cycle metabolic processes within discrete cellular domains. COX is an inner mitochondrial multi-subunit enzyme complex expressed and assembled as a mosaic from nuclear and mitochondrial genomes. A recent review presents the case for COX as a key regulator of mitochondrial ATP production [3]. The authors propose that the evolutionarily driven addition of nuclear-encoded COX subunits provides the host eukaryotic cell with high order control over the ancestral activity of COX subunits encoded by mtDNA genes in the face of fluctuating mitochondrial oxygen tensions and potentially dangerous reactive oxygen species.

Transcriptional Regulation of Mitochondrial Biogenesis

Mitochondrial biogenesis is a key physiological process that is required for normal growth and development and for maintenance of ongoing cellular energy requirements during aging. Of equivalent and/or greater importance is the regulated enhancement of mitochondrial biogenesis upon physiological demand coupled to multiple cellular insults [4]. Accordingly, all cellular survival mechanisms following a variety of disease-related pathophysiological insults are entrained by convergent mechanisms designed to regain homeostatic control of mitochondrial biogenesis. Recent molecular studies represent a clearly defined approach to maximize normative cellular expression of mitochondrial biogenesis for maintenance of cellular energy requirements and as an anti-aging strategy in healthy human populations. It represents a compelling therapeutic strategy for enhancement of cellular expression of mitochondrial biogenesis in diverse human populations afflicted with metabolic, degenerative, neurodegenerative, and metastatic diseases.

The mechanistic foundation of some molecular methods for maintenance and restoration of homeostatic control of mitochondrial biogenesis involves enhanced cellular expression of 2 major regulatory proteins that provide selective protection, transcription, and replication of mitochondrial DNA (mtDNA): 1) Mitochondrial transcription factor A (TFAM) and 2) Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1). TFAM protein is the limiting factor involved in cellular stabilization of mtDNA [5], is a well defined transcriptional activator of mtDNA [6], and is an essential regulator of mtDNA copy number [7]. PGC-1 is a key transcriptional coactivator protein that is intimately involved in the regulation of intermediate energy metabolism with direct physiological linkage to homeostasis of mitochondrial biogenesis. PGC-1 is the major regulator of downstream nuclear gene expression that is required for normal mitochondrial function and homeostatic control of mitochondrial biogenesis. The profound regulatory effects of PGC-1 appear to be dependent on evoked enhancement of cellular cyclic guanosine monophosphate (cGMP) by constitutive nitric oxde (NO) systems [8]. Importantly, TFAM and PGC-1 have been demonstrated to exert interactive regulatory control of normal mitochondrial function and homeostatic control of mitochondrial biogenesis [8].

Mitochondrial Regulatory Genes Associated with Parkinson’s Disease

Etiological factors linked to the development and persistence of Parkinson’s Disease (PD) have been attributed to mitochondrial dysfunction in CNS A9 dopamine-expressing neurons. Previously proposed mechanisms of PD-associated neuronal degeneration have focused on free-radical generation within mitochondria [9]. Many recent studies, however, suggest that impairment of basic mitochondrial integrity may play a key role in the pathogenesis of PD [10–13]. Accordingly, several PD-associated genes interact with pathways regulating mitochondrial function, morphology, and dynamics [11]. It is at this level of mitochondrial integrity that sporadic and genetic PD appears to converge [10,14,15]. Recent studies indicate that two distinct PD-associated genes are required for normative functional integrity of mitochondria [13,16]. Genetic studies have shown that PINK1 is upstream of Parkin in a pathway that regulates mitochondrial morphology and degradation [17–20]. One model proposes that Parkin is a PINK1 substrate activated by phosphorylation, while other studies have failed to demonstrate selective phosphorylation events [21]. Wang et al., 2011, proposed another model, where PINK1 and Parkin bind to the same target: Miro. Additional studies have demonstrated that both PINK1 and Parkin bind to Miro when expressed In HEK293T cells, indicating that the interaction of Miro with PINK1 and Parkin is triggered by depolarization of the mitochondria [11,22].

Mitochondrial motility appears to represent an existential cellular process in neurons. Temporal transit of intact mitochondria from somata to distant axonal or dendritic sites is on the orders of days [11]. The mitochondrion-specific adaptor proteins, Miro and Milton, are regulatory players in mitochondrial motility, as demonstrated by the ability of Miro to prevent PINK1/Parkin-induced mitochondrial shut-down in rat hippocampal axons. Mitochondrial depolarization stabilizes PINK1 on the outer surface of the mitochondrial membrane, promoting its interaction with Miro. This functional interaction allows PINK1 to phosphorylate Miro at Ser156. Subsequent interaction of Parkin with Miro and likely ubiquitination causes Miro to be removed from the membrane and degraded by the proteasome, inducing the release Milton and Kinesin from the mitochondrion [11].

The ability of Parkin to induce Miro degradation is consistent with its ability to ubiquitinate mitofusin [23]. Wang et al., 2011 has identified two Miro peptides that are phosphorylated by PINK1, and one phosphorylation site, Serine 156, which is important for the subsequent expression of Parkin. Their data suggest that PINK1 expression inhibits the expression of downstream Parkin, but the inability of MG132 to prevent this inhibition further suggests that the degradation of Miro may in fact occur after the PINK1-Parkin complex has been removed from the mitochondrial surface and motility has ceased.

Previous reports have demonstrated that in various cell lines, damaged mitochondria can selectively recruit Parkin and are subsequently targeted for mitophagy [24,25]. Wang et al., 2011 demonstrate that this Parkin recruitment also occurs in axons. When Parkin was highly expressed, it was found on non-depolarized mitochondria. These results are consistent with Parkin’s ability to inhibit mitochondrial motility upon overexpression. On the other hand, lower Parkin expression levels induced recruitment of Parkin to mitochondria (by treatment with Antimycin). Parkin recruitment is initiated by the depolarization-induced-stabilization of PINK1 on the mitochondrial surface [16,22,26], and PINK1 is upstream of Parkin in regulating mitochondrial morphology [17–20].

Conclusions

In conclusion, the potential molecular targets described above may represent a defined approach to evaluate normative cellular expression of mitochondrial biogenesis and ongoing mitochondrial viability for maintenance of cellular energy requirements and as an anti-aging strategy in healthy human populations. In light of what has been presented above, primordial signaling may have been instrumental in the establishment of the mitochondrion as a viable eukaryotic organelle. Aberrant regulatory events at the mitochondrial level are proposed as causative factors in a variety of pathophysiological states that associated with very basic metabolic dysfunction.

References

1. Cavalier-Smith T, Origin of mitochondria by intracellular enslavement of a photosynthetic purple bacterium: Proc Biol Sci, 2006; 273; 1943-52, pmid: 16822756

2. Watt IN, Montgomery MG, Runswick MJ, Bioenergetic cost of making an adenosine triphosphate molecule in animal mitochondria: Proc Natl Acad Sci USA, 2010; 107; 16823-27, pmid: 20847295

3. Pierron D, Wildman DE, Huttemann M, Cytochrome c oxidase: Evolution of control via nuclear subunit addition: Biochim Biophys Acta, 2011 [epub ahead of print]

4. Kream RM, Stefano GB, Endogenous morphine and nitric oxide coupled regulation of mitochondrial processes: Med Sci Monit, 2009; 15(12); RA263-68, pmid: 19946245

5. Ekstrand MI, Falkenberg M, Rantanen A, Mitochondrial transcription factor A regulates mtDNA copy number in mammals: Hum Mol Genet, 2004; 13; 935-44, pmid: 15016765

6. Ikeuchi M, Matsusaka H, Kang D, Overexpression of mitochondrial transcription factor a ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction: Circulation, 2005; 112; 683-90, pmid: 16043643

7. Kang D, Kim SH, Hamasaki N, Mitochondrial transcription factor A (TFAM): roles in maintenance of mtDNA and cellular functions: Mitochondrion, 2007; 7; 39-44, pmid: 17280879

8. Nisoli E, Clementi E, Paolucci C, Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide: Science, 2003; 299(5608); 896-99, pmid: 12574632

9. Esch T, Stefano GB, Fricchione GL, Benson H, The role of stress in neurodegenerative diseases and mental disorders: Neuroendocrinology Letters, 2002; 23; 199-208, pmid: 12080279

10. Winklhofer KF, Haass C, Mitochondrial dysfunction in Parkinson’s disease: Biochim Biophys Acta, 2010; 1802; 29-44, pmid: 19733240

11. Wang X, Winter D, Ashrafi G, PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility: Cell, 2011; 147; 893-906, pmid: 22078885

12. Whitworth AJ, Pallanck LJ, The PINK1/Parkin pathway: a mitochondrial quality control system?: J Bioenerg Biomembr, 2009; 41; 499-503, pmid: 19967438

13. Narendra DP, Youle RJ, Targeting mitochondrial dysfunction: role for PINK1 and Parkin in mitochondrial quality control: Antioxid Redox Signal, 2011; 14; 1929-38, pmid: 21194381

14. Kitada S, Krajewska M, Zhang X, Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines: Am J Pathol, 1998; 152; 51-61, pmid: 9422523

15. Valente EM, Abou-Sleiman PM, Caputo V, Hereditary early-onset Parkinson’s disease caused by mutations in PINK1: Science, 2004; 304; 1158-60, pmid: 15087508

16. Geisler S, Holmstrom KM, Skujat D, PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1: Nat Cell Biol, 2010; 12; 119-31, pmid: 20098416

17. Clark IE, Dodson MW, Jiang C, Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin: Nature, 2006; 441; 1162-66, pmid: 16672981

18. Exner N, Treske B, Paquet D, Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin: J Neurosci, 2007; 27; 12413-18, pmid: 17989306

19. Park J, Lee SB, Lee S, Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin: Nature, 2006; 441; 1157-61, pmid: 16672980

20. Poole AC, Thomas RE, Andrews LA, The PINK1/Parkin pathway regulates mitochondrial morphology: Proc Natl Acad Sci USA, 2008; 105; 1638-43, pmid: 18230723

21. Vives-Bauza C, Przedborski S, Mitophagy: the latest problem for Parkinson’s disease: Trends Mol Med, 2011; 17; 158-65, pmid: 21146459

22. Jin SM, Lazarou M, Wang C, Kane LA, Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL: J Cell Biol, 2010; 191; 933-42, pmid: 21115803

23. Karbowski M, Youle RJ, Regulating mitochondrial outer membrane proteins by ubiquitination and proteasomal degradation: Curr Opin Cell Biol, 2011; 23; 476-82, pmid: 21705204

24. Narendra D, Tanaka A, Suen DF, Youle RJ, Parkin is recruited selectively to impaired mitochondria and promotes their autophagy: J Cell Biol, 2008; 183; 795-803, pmid: 19029340

25. Van Laar VS, Arnold B, Cassady SJ, Bioenergetics of neurons inhibit the translocation response of Parkin following rapid mitochondrial depolarization: Hum Mol Genet, 2011; 20; 927-40, pmid: 21147754

26. Narendra DP, Jin SM, Tanaka A, PINK1 is selectively stabilized on impaired mitochondria to activate Parkin: PLoS Biol, 2010; 8; e1000298, pmid: 20126261

In Press

Clinical Research  

Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...

Med Sci Monit In Press; DOI: 10.12659/MSM.951027  

Clinical Research  

Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...

Med Sci Monit In Press; DOI: 10.12659/MSM.950516  

Review article  

Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A Review

Med Sci Monit In Press; DOI: 10.12659/MSM.951283  

Clinical Research  

Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 Adults

Med Sci Monit In Press; DOI: 10.12659/MSM.950938  

Most Viewed Current Articles

17 Jan 2024 : Review article   10,187,196

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

13 Nov 2021 : Clinical Research   3,708,487

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

0:00

14 Dec 2022 : Clinical Research   2,341,643

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   706,524

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750